Scope and Claim Analysis for US Patent 12,478,606 (Vaborbactam + Meropenem for cUTI/AP/CRE in High-Comorbidity Patients)
US Patent 12,478,606 is a method-of-treatment patent centered on using vaborbactam plus meropenem (alone or as a single dosage form) in defined patient subpopulations with complicated urinary tract infection (cUTI), acute pyelonephritis (AP), and broader CRE-associated serious infections, with claim scope driven by (i) comorbidity stratification (Charlson score), (ii) physiologic severity markers (SIRS), (iii) infection subtype and pathogen set, and (iv) administration/dosing logistics (2 g each, IV infusion timing, at least 5 days, q8h option).
Because these are use claims with multiple narrowing dependencies, the patent’s practical enforceability depends on whether an accused regimen matches the claim’s patient-selection criteria and treatment-definition elements, not just the existence of the same drug combination in the same indication.
What is US Patent 12,478,606 claiming at a high level?
Core independent claim theme: treating or ameliorating cUTI or AP with vaborbactam + meropenem in subjects defined by Charlson comorbidity score ≥ 3.
Claim 1 anchor elements (independent)
Claim 1 requires all of the following:
- Indication: “complicated urinary tract infection (cUTI) or acute pyelonephritis (AP)”
- Act: administering a combination of
- vaborbactam (or pharmaceutically acceptable salt), and
- meropenem
- Patient selection: Charlson comorbidity score ≥ 3
Impact: Any infringement analysis must map to Charlson scoring in the treated population at baseline and to the clinical determination that the case is cUTI or AP under the patent’s interpretation.
Claims 2–9 are narrower patient/clinical variations
- Claim 2: subject has cUTI
- Claim 3: subject has AP
- Claim 4: concomitant bacteremia
- Claim 5: treatment duration continues at least five days
- Claim 6: subject is female
- Claims 7–8: renal function thresholds
- CrCl ≥ 40 mL/min
- CrCl ≥ 30 mL/min
- Claim 9: SIRS
Impact: These are dependent claim add-ons. They do not expand independent scope, but they create multiple additional ways to match a regimen if the accused clinician/program uses those sub-criteria.
How does Claim 10 expand scope versus Claim 1 (what does SIRS selection add)?
Claim 10 is a second independent method framework. It still requires:
- cUTI or AP
- vaborbactam + meropenem
- Charlson score ≥ 3
…but it adds a selection step:
- “selecting for treatment a subject having SIRS who is also suffering from cUTI or AP”
Claim 11 adds detailed SIRS-vitals/hematology criteria
Claim 11 specifies example SIRS component-like markers, including at treatment time:
- Temperature: <36°C or >38°C
- Heart rate: >90 bpm
- Respiratory rate: >20/min
- PaCO₂: <4.3 kPa (32 mmHg)
- WBC: >12,000 or <4,000 cells/mm³
- Immature neutrophils: >10%
Impact: If enforcement is pursued against a regimen using “SIRS” broadly, Claim 11 raises the bar for proof of “what SIRS” meant. Still, Claim 10 itself only requires that the subject has SIRS, so Claim 11 is an additional narrowing lane.
What is Claim 12’s selection concept and how does it differ from Claim 10?
Claim 12 is independent and includes:
- selecting for treatment subjects with Charlson ≥ 3 who have cUTI or AP
- administering vaborbactam + meropenem
Compared with Claim 10, Claim 12:
- does not require SIRS as a selection criterion (at the independent level),
- does require Charlson ≥ 3.
Dependent Claims 13–17
- Claim 13: concomitant bacteremia
- Claim 14: duration ≥ 5 days
- Claims 15–16: renal function (CrCl ≥ 40; CrCl ≥ 30)
- Claim 17: pathogen baseline set for cUTI/AP
Impact: Claim 12 can be easier to satisfy than Claim 10 in cases where SIRS is not documented or not determinable, while still requiring Charlson ≥ 3.
Which pathogens are explicitly covered for cUTI/AP in the claims?
Claims 17 and 40 cover cUTI/AP caused by a baseline pathogen list:
- E. coli
- K. pneumoniae
- Enterococcus faecalis
- Proteus mirabilis
- Enterobacter cloacae species complex
- P. aeruginosa
- or combinations thereof
Impact: These pathogen lists operate as additional dependent constraints. If the accused regimen is clearly directed at cUTI/AP in a Charlson-defined population, pathogen identity can still matter for claim matching only if the relevant dependent claim is asserted.
How does the CRE-focused independent claim (Claim 18) broaden the landscape beyond cUTI/AP?
Claim 18 is independent and expands from cUTI/AP to broader CRE serious infection treatment, requiring:
- selecting for treatment a subject with CRE infection that “requires at least 7 days of treatment with intravenous antibiotics”
- administering vaborbactam + meropenem
Claim 19 expands CRE inclusion criteria to infection types
CRE infection is selected from:
- cUTI
- AP
- cIAI
- HABP
- VABP
- bacteremia
- or combinations thereof
Impact: This creates a broader set of attack surfaces in enforcement scenarios across hospital-acquired and ventilator-associated infection contexts, abdominal infections, and bloodstream infection, provided “CRE infection” and the “≥7 days IV antibiotics” requirement are met.
Claim 20 and 21 add comparative clinical outcome assertions
- Claim 20: “less adverse events… compared to… best available therapy”
- Claim 21: “higher success rate… compared to… best available therapy”
Claim 22/41 defines “best available therapy” comparator set
Best available therapy is selected from:
- ciprofloxacin
- polymyxin B
- colistin
- amikacin
- meropenem
- gentamicin
- ertapenem
- tigecycline
- ceftazidime-avibactam
- combinations thereof
Impact: These claims are outcome-based comparison dependent claims. In litigation, matching “best available therapy” depends on what comparator regimen was actually used as “best available therapy” in the specific clinical context or how the patent defines that term in practice.
Claim 23–25 and treatment administration dependents
- Claim 23: Charlson ≥ 3
- Claim 24: Charlson ≥ 5
- Claim 25: SIRS
- Claims 26–27: dose
- vaborbactam about 2 g
- meropenem about 2 g
- Claims 28–31: dosing frequency and infusion completion time
- at least once per day
- every 8 hours (q8h)
- IV infusion
- infusion completed about 3 hours
- Claims 32–33: sequencing/prior-subsequent administration or single dosage form
- Claim 34: optional additional medicaments (broad classes)
Impact: Claim 18 itself sets the CRE/selection and combination. The dependent claims layer dosing and protocol specifics that create many narrower versions for infringement if a specific regimen is used.
What do the repeated dependent claims imply about drafting strategy and claim “coverage density”?
Claims 36–69 largely mirror claims 10/12 dependent structures, reusing the same set of protocol locks:
- duration ≥ 5 days
- renal thresholds (CrCl ≥ 40 and ≥ 30)
- SIRS selection markers for Claim 10 lane
- dosing: 2 g vaborbactam + 2 g meropenem
- administration: at least daily, q8h, IV infusion completed in about 3 hours
- dosing sequence: prior or subsequent
- co-formulation: single dosage form
- add-on meds: antibacterial/antifungal/antiviral/anti-inflammatory/anti-allergic
Interpretation: The claim set is engineered to cover routine real-world clinical protocol decisions that vary between sites and studies (sequence, infusion completion time, renal adjustment inclusion in protocols, duration floors).
How does renal function and duration language shape enforceable scope?
cUTI/AP lane
- “at least five days” appears in multiple dependent claims (e.g., claims 5, 14, 36)
- renal inclusion tiers:
- CrCl ≥ 40 mL/min (claims 7, 15, 37)
- CrCl ≥ 30 mL/min (claims 8, 16, 38)
CRE lane
- “requires at least 7 days of treatment with intravenous antibiotics” is in the independent claim 18 selection criterion
- CRE lane still includes at least daily/q8h/3-hour infusion timing dependent elements
Practical consequence: If an accused regimen treats CRE with an IV duration floor below 7 days for the selection population, that may undercut match to claim 18 even if vaborbactam + meropenem is used. For cUTI/AP, duration floors are lower (≥5 days) in dependent claims, but not in Claim 1 itself.
What patient-comorbidity requirement is enforced across claims?
- Claim 1: Charlson score ≥ 3
- Claim 10: selection includes SIRS and Charlson ≥ 3
- Claim 12: selection includes Charlson ≥ 3
- Claim 18: Charlson ≥ 3 in dependents (23), and Charlson ≥ 5 in dependent (24)
Enforcement posture: The Charlson cutoff is the strongest repeated “gate” in the independent-level cUTI/AP claims and a repeated dependent gate in CRE.
What dosing and administration limitations are built into the claim set?
Dose amounts
- vaborbactam about 2 g (claims 26, 42, 51, 60)
- meropenem about 2 g (claims 27, 43, 52, 61)
These appear as dependent claim limitations tethered to the CRE lane (claim 18) and the cUTI/AP independent claim (claim 1) lanes.
Schedule and infusion
- at least once per day (claims 28, 44, 53, 62)
- every 8 hours (claims 29, 45, 54, 63)
- IV infusion (claims 30, 46, 55, 64)
- infusion completed about 3 hours (claims 31, 47, 56, 65)
Administration sequencing and formulation
- vaborbactam prior or subsequent to meropenem (claims 32, 48, 57, 66)
- single dosage form (claims 33, 49, 58, 67)
Combination with additional agents
- optional add-on medicaments across lanes:
- antibacterial, antifungal, antiviral, anti-inflammatory, anti-allergic agents (claims 34, 50, 59, 68)
Impact: These elements can be central for infringement if an accused protocol differs in frequency, infusion completion timing, or dosing amounts.
How does Claim 69 further narrow the cUTI/AP lane?
Claim 69 adds:
- subject is a human suffering from moderate or severe liver disease
Impact: It is a dependent narrowing element. It provides another claim-matching path if liver disease populations are targeted under the same vaborbactam + meropenem protocol and Charlson ≥ 3 is present (since it is within Claim 1’s framework).
Where does the patent sit in the broader competitive landscape for vaborbactam + meropenem?
From the claim language, the competitive differentiation targets:
- high-comorbidity / severity patient strata (Charlson ≥ 3, SIRS options)
- CRE requiring longer IV course (≥7 days)
- specific protocol characteristics (q8h, ~3-hour infusion completion, ~2 g doses)
This is the type of claim that can block:
- clinical guideline-driven adoption in defined subpopulations, and
- protocol-driven off-label use that matches patient-selection and dosing parameters.
Because the independent cUTI/AP claims are not restricted to CRE only, the competitive risk is not confined to CRE-only products. The CRE independent claim, however, is structurally broader in infection type scope while anchoring duration/IV requirement via “requires at least 7 days.”
What does the claim set imply for potential design-around strategies?
The most salient design-around levers created by the claim text are:
-
Charlson score gating
- avoid use in populations where Charlson ≥ 3 is not met, or avoid claiming/recording Charlson thresholds in the population targeted (litigation depends on evidence of selection at the time of treatment).
-
SIRS-based selection
- avoid protocols designed around SIRS selection criteria (affects Claim 10 lane, but does not remove Claim 1 and 12 Charlson-based coverage).
-
Duration floors
- for CRE, avoid regimens where the treated cohort does not meet “requires at least 7 days” IV antibiotic treatment.
- for cUTI/AP, avoid regimens with duration below the “at least five days” dependent claim thresholds (though Claim 1 itself does not hardwire duration).
-
Dose and infusion timing
- alter dosing amounts, infusion duration, or dosing frequency so dependent claims on “about 2 g,” “every 8 hours,” or “infusion completed about 3 hours” are harder to match.
-
Formulation and sequencing
- use separate dosage forms or altered sequencing to impact “single dosage form” and sequencing dependent claims.
Important structural point: Claim 1 and Claim 18 independent claims are combination-administering methods with selection criteria. Design-arounds that only change formulation may not avoid the independent gate.
Timeline and exclusivity
No reliable timeline can be produced from the claim text alone. A full exclusivity/timeline analysis requires the application filing date, priority chain, grant date, terminal disclaimer terms, and any FDA regulatory exclusivities or patent term adjustments.
Key Takeaways
- US Patent 12,478,606 is built around method-of-treatment claims for vaborbactam + meropenem with patient-selection gates: Charlson comorbidity score ≥ 3 for cUTI/AP independent claims; CRE requiring ≥7 days IV antibiotics for the CRE independent claim.
- The claim set densifies coverage with dependent limitations on SIRS, bacteremia, CrCl thresholds, minimum treatment duration, specific pathogen sets, and protocol administration (about 2 g each dose, q8h option, IV infusion completed in about 3 hours, single dosage form vs sequencing).
- The CRE lane broadens to infection types beyond cUTI/AP (cIAI, HABP, VABP, bacteremia) while adding comparative outcome language via “less adverse events” and “higher success rate” versus “best available therapy.”
- Enforceability hinges on whether an accused regimen matches the patient stratification and treatment-definition elements, not merely the presence of vaborbactam + meropenem.
FAQs
1) Does US 12,478,606 cover vaborbactam plus meropenem for all cUTI/AP patients?
No. The independent cUTI/AP methods require Charlson comorbidity score ≥ 3; broader coverage depends on dependent claim matches.
2) Are SIRS criteria required to infringe US 12,478,606?
No. SIRS is required for the Claim 10 independent lane and appears in dependent claims, but Claim 1 and Claim 12 are not SIRS-dependent.
3) What dosing details are actually claim-limited?
Dependent claims specify about 2 g vaborbactam and about 2 g meropenem, with IV infusion protocol elements including q8h and infusion completion of about 3 hours.
4) How does the CRE claim define treatment duration?
Claim 18 requires that the CRE infection “requires at least 7 days of treatment with intravenous antibiotics.”
5) What comparator drugs are named for the CRE outcome claims?
The “best available therapy” comparator list includes ciprofloxacin; polymyxin B; colistin; amikacin; meropenem; gentamicin; ertapenem; tigecycline; ceftazidime-avibactam; and combinations.
References (APA)
- US Patent 12,478,606 (claims text provided in prompt).
